Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Implantable Cardioverter Defibrillator Programming Characteristics, Shocked Rhythms, and Survival Among Patients Under Thirty Years of Age.

Chang PM, Powell BD, Jones PW, Carter N, Hayes DL, Saxon LA.

J Cardiovasc Electrophysiol. 2016 Oct;27(10):1183-1190. doi: 10.1111/jce.13038. Epub 2016 Jul 28.

PMID:
27334356
2.

Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT.

Tompkins CM, McNitt S, Polonsky B, Daubert JP, Wang PJ, Moss AJ, Zareba W, Kutyifa V.

J Cardiovasc Electrophysiol. 2017 Jan;28(1):94-102. doi: 10.1111/jce.13102. Epub 2016 Oct 27.

PMID:
27696593
3.

Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.

Buber J, Luria D, Gurevitz O, Bar-Lev D, Eldar M, Glikson M.

Europace. 2014 Feb;16(2):227-34. doi: 10.1093/europace/eut302. Epub 2013 Oct 9.

PMID:
24108231
4.

Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.

Tompkins CM, Kutyifa V, Arshad A, McNitt S, Polonsky B, Wang PJ, Moss AJ, Zareba W.

J Cardiovasc Electrophysiol. 2015 Aug;26(8):862-871. doi: 10.1111/jce.12701. Epub 2015 Jun 17.

PMID:
25929699
5.

Association of Antitachycardia Pacing or Shocks With Survival in 69,000 Patients With an Implantable Defibrillator.

Strickberger SA, Canby R, Cooper J, Coppess M, Doshi R, John R, Connolly AT, Roberts G, Karst E, Daoud EG.

J Cardiovasc Electrophysiol. 2017 Apr;28(4):416-422. doi: 10.1111/jce.13170. Epub 2017 Feb 17.

PMID:
28128491
6.

Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.

Li CH, Lin YJ, Huang JL, Wu TJ, Cheng CC, Lin WS, Tuan TC, Chang SL, Lo LW, Hu YF, Chao TF, Chung FP, Tsai CF, Tsao HM, Chen SA.

J Cardiovasc Electrophysiol. 2012 Jul;23(7):750-6. doi: 10.1111/j.1540-8167.2011.02288.x. Epub 2012 Feb 21.

PMID:
22353378
7.

Inappropriate cardioverter-defibrillator discharge continues to be a major problem in clinical practice.

Jodko Ł, Kornacewicz-Jach Z, Kaźmierczak J, Rzeuski R, Zielonka J, Kaliszczak R, Safranow K.

Cardiol J. 2009;16(5):432-9.

PMID:
19753522
8.

Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).

Ruwald AC, Schuger C, Moss AJ, Kutyifa V, Olshansky B, Greenberg H, Cannom DS, Estes NA, Ruwald MH, Huang DT, Klein H, McNitt S, Beck CA, Goldstein R, Brown MW, Kautzner J, Shoda M, Wilber D, Zareba W, Daubert JP.

Circ Arrhythm Electrophysiol. 2014 Oct;7(5):785-92. doi: 10.1161/CIRCEP.114.001623. Epub 2014 Aug 18.

PMID:
25136077
9.

Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.

Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA 3rd, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ.

Heart Rhythm. 2013 Feb;10(2):214-8. doi: 10.1016/j.hrthm.2012.10.003. Epub 2012 Oct 4.

PMID:
23041573
10.

Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.

Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young TL, Curtis F, Collier A, Parfrey PS, Connors SP.

Circ Arrhythm Electrophysiol. 2016 Mar;9(3). pii: e003589. doi: 10.1161/CIRCEP.115.003589.

PMID:
26966288
11.

Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.

Dichtl W, Wolber T, Paoli U, Brüllmann S, Stühlinger M, Berger T, Spuller K, Strasak A, Pachinger O, Haegeli LM, Duru F, Hintringer F.

Clin Cardiol. 2011 Jul;34(7):433-6. doi: 10.1002/clc.20910. Epub 2011 Jun 15.

12.

Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.

Schaer B, Kühne M, Reichlin T, Osswald S, Sticherling C.

Europace. 2016 Feb;18(2):227-31. doi: 10.1093/europace/euv188. Epub 2015 Jun 10.

PMID:
26063686
13.

The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients.

Fischer A, Ousdigian KT, Johnson JW, Gillberg JM, Wilkoff BL.

Heart Rhythm. 2012 Jan;9(1):24-31. doi: 10.1016/j.hrthm.2011.08.005. Epub 2011 Aug 9.

PMID:
21835150
14.

Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.

Powell BD, Saxon LA, Boehmer JP, Day JD, Gilliam FR 3rd, Heidenreich PA, Jones PW, Rousseau MJ, Hayes DL.

J Am Coll Cardiol. 2013 Oct 29;62(18):1674-1679. doi: 10.1016/j.jacc.2013.04.083. Epub 2013 Jun 27.

15.

Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database.

Lunati M, Proclemer A, Boriani G, Landolina M, Locati E, Rordorf R, Daleffe E, Ricci RP, Catanzariti D, Tomasi L, Gulizia M, Baccillieri MS, Molon G, Gasparini M; ClinicalService Cardiological Centres.

Europace. 2016 Sep;18(9):1391-8. doi: 10.1093/europace/euv420. Epub 2016 Jan 29.

PMID:
26826135
16.

Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK; PREPARE Study Investigators.

J Am Coll Cardiol. 2008 Aug 12;52(7):541-50. doi: 10.1016/j.jacc.2008.05.011.

17.

Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications.

Link MS, Bockstall K, Weinstock J, Alsheikh-Ali AA, Semsarian C, Estes NAM 3rd, Spirito P, Haas TS, Rowin EJ, Maron MS, Maron BJ.

J Cardiovasc Electrophysiol. 2017 May;28(5):531-537. doi: 10.1111/jce.13194. Epub 2017 Mar 31.

PMID:
28240435
18.

Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.

Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R, Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK, Krahn AD, Wolfe LG, Feinstein S, Ellenbogen KA.

Europace. 2013 Mar;15(3):347-54. doi: 10.1093/europace/eus316. Epub 2012 Sep 21.

PMID:
23002195
19.

Long-term benefit of first-line peri-implantable cardioverter-defibrillator implant ventricular tachycardia-substrate ablation in secondary prevention patients.

Acosta J, Cabanelas N, Penela D, Fernández-Armenta J, Andreu D, Borràs R, Korshunov V, Cabrera M, Vasanelli F, Arbelo E, Guasch E, Martínez M, Tolosana JM, Mont L, Berruezo A.

Europace. 2017 Jun 1;19(6):976-982. doi: 10.1093/europace/euw096.

PMID:
27353322
20.

Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.

Orgeron GM, James CA, Te Riele A, Tichnell C, Murray B, Bhonsale A, Kamel IR, Zimmerman SL, Judge DP, Crosson J, Tandri H, Calkins H.

J Am Heart Assoc. 2017 Jun 6;6(6). pii: e006242. doi: 10.1161/JAHA.117.006242.

Supplemental Content

Support Center